Intranasal omalizumab does not increase serum IgE levels

November 22, 2017

(HealthDay)—In patients with birch pollen allergy, intranasal administration of omalizumab does not result in relevant change of allergen-specific and total immunoglobulin E (IgE) levels, according to a pilot study published online Oct. 30 in Allergy.

Julia Eckl-Dorna, M.D., Ph.D., from the Medical University of Vienna, and colleagues performed a double-blind, placebo-controlled trial to assess the effect of a challenge involving intranasal administration of major birch pollen allergen Bet v 1, , or placebo on the levels of total and allergen-specific IgE in patients with birch pollen allergy. Measurements of total and allergen-specific IgE, immunoglobulin G, and basophil sensitivity were taken before and eight weeks after the challenge. Controls included subjects treated subcutaneously with either omalizumab or placebo.

The researchers found that intranasal challenge with Bet v 1 induced increases of Bet v 1-specific IgE levels by a median of 59.2 percent, which was significantly more than in the other treatment groups. In patients challenged with omalizumab, there were no relevant changes in allergen-specific and total IgE levels. Significant rises in total IgE and the presence of IgE-omalizumab complexes were seen with subcutaneous administration of omalizumab.

"Intranasal administration of allergen induced rises of allergen-specific IgE levels whereas intranasal administration of omalizumab did not enhance systemic total or allergen-specific IgE levels," conclude the authors.

One author disclosed financial ties to the pharmaceutical industry.

Explore further: Omalizumab protects against early, late allergic responses

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Omalizumab protects against early, late allergic responses

June 9, 2017
(HealthDay)—For patients with a significant response to allergen challenge, omalizumab induces protective effects against early (EAR) and late allergic reactions (LAR), according to a study published online June 5 in Allergy.

Omalizumab effective for chronic spontaneous urticaria

March 31, 2016
(HealthDay)—Omalizumab is effective in patients with moderate-to-severe chronic spontaneous urticaria (CSU) symptoms and angioedema unresponsive to high doses of antihistamine treatment, according to a study published online ...

Markers that predict omalizumab response identified

May 2, 2016
(HealthDay)—Baseline serum periostin levels and levels of serum free immunoglobulin E (IgE) during treatment follow-up may be useful in assessing response to omalizumab treatment for asthma, according to a study published ...

Immunotherapy efficacy up with Gal-1/SIT co-administration

July 24, 2017
(HealthDay)—Galectin-1 (Gal-1), allergen-specific immunotherapy (SIT) co-administration may suppress allergic responses in the intestine more than use of SIT or Gal-1 alone, according to an experimental study published ...

'Apple allergy': Symptoms could be significantly reduced with apple-allergen treatment

October 19, 2012
The food allergy associated with birch pollen is a condition commonly found alongside an allergy to birch pollen. Sufferers are plagued by swelling and reddening or itching in the mouth and throat area, for example when they ...

Local allergic rhinitis responds to allergen immunotherapy

March 29, 2016
(HealthDay)—Dermatophagoides pteronyssinus (DP) subcutaneous allergen immunotherapy (AIT) seems safe and effective for local allergic rhinitis (LAR), according to a study published online March 23 in Allergy.

Recommended for you

Composition of complex sugars in breast milk may prevent future food allergies

June 12, 2018
The unique composition of a mother's breastmilk may help to reduce food sensitization in her infant, report researchers at the University of California San Diego School of Medicine with colleagues in Canada.

Drug may quell deadly immune response when trauma spills the contents of our cells' powerhouses

June 11, 2018
When trauma spills the contents of our cell powerhouses, it can evoke a potentially deadly immune response much like a severe bacterial infection.

Immune system does not recover despite cured hepatitis C infection

June 11, 2018
Changes to the immune system remain many years after a hepatitis C infection heals, a new study by researchers at Karolinska Institutet, Sweden, and Hannover Medical School, Germany, shows. The findings, presented in Nature ...

Food allergies connected to children with autism spectrum disorder

June 8, 2018
A new study from the University of Iowa finds that children with autism spectrum disorder (ASD) are more than twice as likely to suffer from a food allergy than children who do not have ASD.

A 'super' receptor that helps kill HIV infected cells

June 8, 2018
While treatments for HIV mean that the disease is no longer largely fatal, the world still lacks a true therapy that can eradicate the virus across a globally—and genetically different—population.

Antibody blocks inflammation, protects mice from hardened arteries and liver disease

June 6, 2018
Researchers at University of California San Diego School of Medicine discovered that they can block inflammation in mice with a naturally occurring antibody that binds oxidized phospholipids (OxPL), molecules on cell surfaces ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.